Adv Pharm Bull. 2013;3(2):353-8. doi: 10.5681/apb.2013.057. Epub 2013 Aug 20.

GABAB Receptor Blockade Prevents Antiepileptic Action of Ghrelin in the Rat Hippocampus.

Advanced pharmaceutical bulletin

Zohreh Ataie, Shirin Babri, Mina Ghahramanian Golzar, Hadi Ebrahimi, Fariba Mirzaie, Gisou Mohaddes

PMID: 24312860 PMCID: PMC3848211 DOI: 10.5681/apb.2013.057

Abstract

PURPOSE: Ghrelin has been shown to have antiepileptic function. However, the underlying mechanisms by which, ghrelin exerts its antiepileptic effects are still unclear. In the present study; we investigated antiepileptic mechanism of ghrelin through GABAB receptors using CGP35348 (selective GABAB receptor antagonist).

METHODS: Male Wistar rats' hippocampi were bilaterally microinjected with the single dose or 10-day ghrelin (0.3 nmol/µl/side). CGP35348, GABAB receptor antagonist, (12.5 µg/µl/side) or saline injected into the dorsal hippocampus 20 minutes before ghrelin administration. Thirty min after ghrelin microinjection, a single convulsive dose of pentylenetetrazole (PTZ) (50 mg/kg) was injected intraperitoneally (i.p). Afterwards, seizure duration and total seizure score (TSS) were assessed for 30 minutes in all animals.

RESULTS: Our results demonstrated that acute and chronic intrahippocampal (i.h.) injection of ghrelin could significantly (p<0.001) attenuate the severity of seizures. Ghrelin 0.3 nmol/µl/side decreased duration of seizure significantly both in acute (p<0.001) and chronic (p<0.01) injections. The ghrelin antiepileptic effect was completely antagonized by GABAB blockade. The suppression of both duration and TSS induced by ghrelin in hippocampus was significantly (p<0.001) blocked by CGP35348 in PTZ-induced seizures.

CONCLUSION: In summary, our findings suggest that GABAB receptors may mediate the antiepileptic action of ghrelin in the hippocampus. Therefore, it is possible to speculate that ghrelin acts in the hippocampus to modulate seizures via GABA.

Keywords: CGP35348; Epilepsy; Ghrelin; Hippocampus; PTZ

References

1. Biochem Biophys Res Commun. 2002 Dec 20;299(5):739-43 - PubMed
2. Epilepsy Behav. 2009 May;15(1):73-7 - PubMed
3. Neuron. 2003 Feb 20;37(4):649-61 - PubMed
4. Epilepsia. 2001;42 Suppl 3:8-12 - PubMed
5. Toxicol Pathol. 2007 Dec;35(7):984-99 - PubMed
6. Curr Neuropharmacol. 2007;5(2):115-25 - PubMed
7. Prog Neurobiol. 2008 Apr;84(4):363-404 - PubMed
8. Neurosci Lett. 2009 Mar 27;453(1):58-61 - PubMed
9. Epilepsy Res. 2008 May;79(2-3):187-200 - PubMed
10. Epilepsia. 2005 Jul;46(7):1133-9 - PubMed
11. Physiol Rev. 2004 Jul;84(3):835-67 - PubMed
12. Endocrinology. 2004 Jun;145(6):2607-12 - PubMed
13. Front Neuroendocrinol. 2004 Apr;25(1):27-68 - PubMed
14. Neurosci Lett. 2003 May 1;341(2):151-5 - PubMed
15. Curr Top Med Chem. 2005;5(1):3-14 - PubMed
16. Eur J Pharmacol. 1990 Oct 2;187(1):27-38 - PubMed
17. J Pharmacol Exp Ther. 2002 Dec;303(3):1102-13 - PubMed
18. Neurobiol Dis. 2010 Mar;37(3):704-10 - PubMed
19. Curr Neuropharmacol. 2009 Mar;7(1):37-49 - PubMed
20. J Clin Invest. 2006 Dec;116(12):3229-39 - PubMed
21. Epilepsy Res. 2008 Jan;78(1):50-9 - PubMed
22. Neurosci Lett. 2010 Aug 2;479(3):226-30 - PubMed
23. Pituitary. 2007;10(3):213-25 - PubMed
24. Brain Res Bull. 2008 Mar 28;75(5):598-609 - PubMed
25. Physiol Rev. 2005 Apr;85(2):495-522 - PubMed
26. Endocrinology. 2008 May;149(5):2191-9 - PubMed
27. Peptides. 2007 Jun;28(6):1214-9 - PubMed
28. Biochem Biophys Res Commun. 2004 Jan 16;313(3):635-41 - PubMed
29. Neuron. 2006 May 18;50(4):589-601 - PubMed
30. Neuropeptides. 2009 Aug;43(4):295-302 - PubMed
31. Nat Neurosci. 2006 Mar;9(3):381-8 - PubMed
32. Nature. 2001 Jan 11;409(6817):194-8 - PubMed

Publication Types

• Journal Article